The extensive use of antibiotics worldwide during the last decades has led to a threatening situation where a large number of bacteria have developed resistance against conventional antibiotics. This has resulted in a number of infectious diseases, in some cases life-threatening, for which limited treatment regimens exists.
The number of multi-resistant bacteria is constantly increasing and if the strategy for combating infections is not significantly changed in the coming years, the problems related to resistant bacteria will escalate even further. As a result, development of new effective antimicrobial compounds and treatment alternatives is an important part of the European action plan against the rising threats from antimicrobial resistance.
It is crucial to develop new strategies for treatment of bacterial infections originating from planktonic bacterial species but also for infections caused by multispecies biofilms. In this sense it is not only important to develop new active compounds for infections but also to use these in a strategic way, for instance by local administration when systemic administration is not required. The possibility to reduce doses and treatment periods should also be considered when developing new treatment strategies.